DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Maraviroc
Maraviroc
HIV Tropism Testing for Maraviroc Response
Review CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection
Product Monograph for CELSENTRI
The CCR5-Delta32 Variant Might Explain Part of the Association Between COVID-19 and the Chemokine-Receptor Gene Cluster
Australian Public Assessment Report for Maraviroc
Selected Properties of Maraviroc
A Randomized, Controlled Study on the Safety and E Cacy of Maraviroc
Emtricitabine and Tenofovir Alafenamide
SELZENTRY (Maraviroc) Tablets, for Oral Use • Hepatotoxicity Accompanied by Severe Rash Or Systemic Allergic Reaction
Cytokines and Chemokines in SARS-Cov-2 Infections—Therapeutic Strategies Targeting Cytokine Storm
Design, Chemical Synthesis and Biological Evaluation of Potential New Antiviral Agents
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology Xuanmao Jiao1, Omar Nawab1,2,Tejal Patel2, Andrew V
Leronlimab, a Humanized Monoclonal Antibody to CCR5, Blocks Breast Cancer Metastasis and Enhances Cell Death Induced by DNA Dama
Extracts of the Medicinal Herb Sanguisorba Officinalis Inhibit the Entry of Human Immunodeficiency Virus-1
Reference ID: 4219844
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows in Vitro Activity Against R5 Tropic HIV-2 Clinical Isolates
Cytodyn Inc. (Exact Name of Registrant As Specified in Its Charter)
Design, Synthesis, and Structure-Activity Relationship Investigation of 3’,4’-Disubstituted Pyranochromone Derivatives with Diverse Biological Activities
Top View
Maraviroc (Selzentry®)
Antiviral Drugs in the Treatment of Aids: What Is in the Pipeline ?
Cost-Effectiveness of Maraviroc for Antiretroviral Treatment- Gob.Mx/00Cifras/Proy/ [Accessed May 5, 2008]
Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) Initiating Treatment with ATRIPLA and Periodically During Tablets, for Oral Use Treatment
Maraviroc (Celsentri)
Anti-Hiv Agents: a Step Towards Future
Enhanced Delivery of Actives Through Skin from Patches
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
TABLE 2. HIV Treatment Pipeline 2003–2012 Class Drug Name Generic Name Brand Name Sponsor 2003 2004 2005 2006 2007 2008 2009 2
Cervicovaginal and Rectal Fluid As a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design
Drug Resistance of Human Immunodeficiency Virus and Overcoming It by Natural Products
Ccr5 Antagonists in the Treatment of Treatment-Naïve Patients Infected with Ccr5 Tropic Hiv-1
Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles for Long-Acting Prevention of HIV-1 Vaginal Transmission
Celsentri, INN-Maraviroc
Maraviroc Viiv Healthcare Pty Ltd PM-2010-02896-3-2 Date of Finalisation: 12 May 2013
Labeled Maraviroc
Tea Polyphenols As Natural Products for Potential Future Management of HIV Infection
Viiv Healthcare Presents Phase III Data Comparing Once-Daily